Clinical nutrition by condition: what actually changes when you have a diagnosis

TL;DR. Once a diagnosis attaches to a patient, "eat real food" gives way to medical nutrition therapy (MNT) — specific, evidence-graded nutrient targets and patterns tied to the disease. The ADA recognized carb restriction as a medical option in 2019; DiRECT (Lean 2018) showed durable T2D remission in primary care. NAFLD's first-line therapy is fructose reduction plus 7–10 percent weight loss. DASH and the sodium-to-potassium ratio outperform sodium restriction alone. CKD protein targets reverse across the dialysis transition. Gout's strongest dietary signal is now fructose, not just purines. IBS responds to Monash's low-FODMAP elimination-and-reintroduction protocol. Pediatric Crohn's induction responds to exclusive enteral nutrition. Celiac requires strict gluten avoidance at the 20 ppm threshold. PREDIMED (2013) is the RCT case for the Mediterranean diet. Eating-disorder recovery centers on refeeding-syndrome management and the absence of "good food / bad food" framing.

Important. This is education, not medical advice. MNT for any condition below must be individualized to comorbidities, medications (especially insulin, sulfonylureas, anticoagulants, diuretics, RAAS inhibitors, binders), pregnancy or lactation, life stage, and food access. Ask your physician for a referral to a Registered Dietitian Nutritionist (RDN/RD), ideally one with relevant board certification (CDCES for diabetes; CSR for renal; CEDS-C / CEDRD for eating disorders; CSO for oncology). Your RDN writes the prescription, monitors it, and adjusts as your labs change.

What you'll learn

• Carb counting in T2D and what the ADA repositioning of low-carb means.
• Why NAFLD/MASLD responds to fructose restriction and modest weight loss before pharmacology.
• Why DASH's sodium-to-potassium ratio matters more than sodium alone.
• How CKD protein targets shift across the dialysis transition, and the pre-dialysis fluid-restriction myth.
• How fructose joined purines as a primary dietary trigger for gout.
• The Monash low-FODMAP protocol — elimination, reintroduction, personalization.
• Why EEN is first-line for pediatric Crohn's induction; where CDED and Mediterranean fit.
• What "gluten-free" actually means at 20 ppm, and celiac vs. NCGS vs. wheat allergy.
• Why PREDIMED is the strongest RCT evidence for the Mediterranean diet.
• Why refeeding syndrome and the absence of "good food / bad food" framing are non-negotiable.

1. Type 2 diabetes — carb counting and remission

Diabetes MNT is organized around the ADA's annual Standards of Medical Care (Krause Ch 30, Jessica Jones). Adult non-pregnant A1C target is below 7 percent (below 8 percent for older or comorbid adults); pregnancy targets are tighter. Carbohydrate counting — quantifying carbs in grams so insulin doses match via an insulin-to-carb ratio — works because postprandial glucose is driven primarily by carbohydrate quantity, secondarily by type (glycemic index), fiber, fat, protein, and meal sequence.

The bigger story is the ADA's shift on carb restriction. For decades it recommended 45–65 percent of calories from carbohydrate. The 2019 ADA Consensus Report (Evert et al., Diabetes Care) formally recognized low-carb (below 26 percent) and very-low-carb / ketogenic (below 50 g/day) patterns as evidence-supported options. Carb restriction is now a medical option, not a fringe position.

The remission case rests on two trials. The Newcastle 800-kcal VLCD study (Lim et al., Diabetologia 2011) showed rapid weight loss reversed pancreatic and liver fat and restored beta-cell function in newly diagnosed T2D. DiRECT (Lean et al., The Lancet 2018) extended this to UK primary care: 46 percent of intervention patients in remission at one year, 36 percent at two years (Lean 2019), tracking weight loss almost linearly. Hallberg et al. (Virta Health, Diabetes Therapy 2018) reported sustained reversal in 60–80 percent on nutritional ketosis, with most discontinuing insulin.

Fasting insulin catches resistance years before fasting glucose moves; most physicians do not order it. A1C is misleading in conditions altering red-cell turnover (hemoglobinopathies, transfusion, iron deficiency, CKD). Diabetes-specific eating disorders (diabulimia in T1, BED in T2) must be screened for. Refer to a CDCES-credentialed RDN.

2. NAFLD / MASLD — fructose reduction first, then weight loss

Nonalcoholic fatty liver disease — renamed metabolic dysfunction–associated steatotic liver disease (MASLD) in 2023 — has overtaken alcoholic liver disease as the most common chronic liver disease in the U.S. Krause Ch 29 (Hasse and Matarese) treats MASLD as a hepatic manifestation of metabolic syndrome.

The biochemistry: roughly 100 percent of an oral fructose load reaches the liver, bypasses the phosphofructokinase brake on glycolysis, drives de novo lipogenesis, generates uric acid, and produces methylglyoxal (glycating 250x faster than glucose). The mechanism resembles ethanol, which is why Lustig calls fructose "the alcohol without the buzz."

First-line therapy is dietary. Resmetirom (FDA-approved 2024 for biopsy-confirmed MASH with fibrosis) is the first specific drug; pioglitazone, vitamin E, and GLP-1 agonists have intermediate evidence. All major guidelines call for 7–10 percent weight loss as primary intervention, stronger histologic response at 10 percent. Cutting added sugar (especially HFCS beverages) reduces hepatic fat within days, before measurable weight loss. The Mediterranean pattern has the strongest pattern-level evidence (Plaz Torres et al., Nutrients 2019). Lab markers: ALT (true upper limit closer to 25 IU/L than the 40 most labs flag), AST, GGT, FIB-4, FibroScan. Pediatric MASLD is rising — up to 20 percent of U.S. children. Alcohol abstinence is appropriate during active disease.

3. Hypertension — DASH and the sodium-to-potassium ratio

DASH (Appel et al., NEJM 1997) demonstrated that a pattern emphasizing fruits, vegetables, whole grains, low-fat dairy, lean protein, nuts, and legumes lowered SBP by 11.4 mmHg and DBP by 5.5 mmHg in hypertensive participants — comparable to a single antihypertensive. DASH-Sodium (Sacks et al., NEJM 2001) showed additive benefit at lower sodium.

The mechanism is not just sodium reduction. DASH is high in potassium (~4,700 mg/day, equal to the AI), magnesium, calcium, and fiber, all of which independently lower BP. The relevant ratio is sodium-to-potassium. Most U.S. adults consume roughly twice the CDRR of sodium (3,400 vs. 2,300 mg) and half the AI of potassium (2,500 vs. 4,700 mg). Fixing the ratio matters more than driving sodium toward zero, and is usually easier — eating more potassium-rich foods (leafy greens, beans, lentils, sweet potato, banana, avocado, salmon, tomato) shifts it without the adherence problems of severe sodium restriction.

Two caveats. Salt sensitivity varies — African Americans, older adults, and people with diabetes or CKD respond more strongly. In CKD and heart failure with RAAS blockade, potassium-rich foods may be contraindicated. Lustig argues hyperinsulinemia drives renal sodium retention; the UK's 2006–2012 processed-food sodium mandate is credited with a ~40 percent stroke reduction, and the same approach to sugar would likely be at least as effective.

4. Chronic kidney disease — protein, phosphate, and the fluid myth

CKD nutrition is one of the most complex MNT areas because targets reverse across the dialysis transition. Krause Ch 35 (Wilkens, Shanaman, Juneja) and MNHD Ch 96 (Shah, Rhee, Kopple) are the references. Staging is by eGFR (Stage 3a 45–59; 3b 30–44; 4 15–29; 5 below 15 or on dialysis).

Pre-dialysis (Stages 3–5 not on dialysis), protein target is 0.6–0.8 g/kg/day; meta-analyses since MDRD show modest progression slowing, clearer in diabetic CKD. Plant-dominant protein (legumes, soy, nuts) reduces renal acid load compared with animal protein at the same intake — the basis of PLADO. Phosphorus restriction is essential; inorganic phosphate additives in processed food (sodium phosphate, phosphoric acid in colas) are nearly 100 percent absorbed, while organic phosphate in plants is 40–50 percent and in animal protein 60–70 percent. Phosphate binders (calcium acetate, sevelamer, lanthanum) bind dietary phosphate with meals. Potassium is restricted only when serum potassium is elevated — reflexive restriction blocks intake of the very foods DASH recommends.

On dialysis, protein targets rise sharply — 1.2 g/kg/day on hemodialysis, 1.2–1.5 g/kg/day on peritoneal dialysis — because dialysate losses are substantial and protein-energy wasting drives mortality. Adequacy: Kt/V (eKt/V ≥1.2), URR (≥65 percent), nPNA (0.8–1.4 g/kg/day).

The pre-dialysis fluid-restriction myth: patients with Stage 3 CKD often believe they must restrict fluids. Pre-dialysis patients with preserved urine output should maintain normal hydration (~2–3 L/day) unless they have heart failure, edema, or hyponatremia. Fluid restriction applies when urine output drops and on dialysis (typically 1–1.5 L/day plus urine output). The myth probably originates from generalizing dialysis guidance. Refer to a CSR-credentialed RDN.

5. Gout — fructose joins purines

Gout was once treated as a purine-overconsumption disease. The biochemistry is correct — uric acid is the breakdown product of purines via xanthine oxidase, and hyperuricemia above ~6.8 mg/dL precipitates monosodium urate crystals into joints. But the dietary intervention has updated.

Krause and modern rheumatology now flag fructose as a primary dietary trigger alongside high-purine foods (organ meats, anchovies, sardines, mussels, beer) and alcohol. Mechanism: hepatic fructose phosphorylation depletes intracellular phosphate, activates AMP deaminase, and shunts AMP toward uric acid via IMP and xanthine. Choi et al. (BMJ 2008; JAMA 2010) showed men consuming two or more SSBs per day had 85 percent higher gout risk than those consuming less than one per month, independent of meat and alcohol.

Practical MNT: reduce SSBs and HFCS processed food to near zero; moderate but do not eliminate organ meats and oily fish (cardioprotective omega-3s usually win the trade-off); limit beer especially (guanosine is more uricogenic); maintain hydration; pursue 5–10 percent weight loss slowly (rapid loss can precipitate flares); 500 mg/day vitamin C modestly lowers uric acid; low-fat dairy is uricosuric and protective. Allopurinol or febuxostat are the standard xanthine oxidase inhibitors; lifestyle is adjunctive.

6. IBS — Monash low-FODMAP elimination and reintroduction

IBS (Rome IV: recurrent abdominal pain ≥1 day/week with altered stool form or frequency) affects ~10 percent of adults globally. The strongest dietary intervention is the low-FODMAP diet developed by Monash University (Shepherd, Muir, Gibson).

FODMAPs: Fermentable Oligosaccharides (fructans in wheat, onion, garlic; GOS in legumes), Disaccharides (lactose), Monosaccharides (excess fructose in honey, apples, mango, HFCS), And Polyols (sorbitol, mannitol, xylitol, erythritol). All four classes are poorly absorbed in the small intestine, draw water osmotically, and ferment rapidly in the colon.

The Monash protocol has three phases. Elimination (2–6 weeks): strict low-FODMAP using Monash's serving-size thresholds; relief in ~70–75 percent (Halmos et al., Gastroenterology 2014; Marsh et al., Eur J Nutr 2016 meta-analysis). Reintroduction (6–8 weeks): systematic challenges with one FODMAP subgroup at a time to identify individual triggers and tolerance. Personalization: long-term diet excluding only the subgroups that provoke symptoms in this patient.

The protocol is not a permanent diet. Long-term strict low-FODMAP intake reduces beneficial Bifidobacterium, restricts variety, and risks nutritional inadequacy. Monash recommends RDN supervision for elimination and especially reintroduction; many patients err by remaining in elimination indefinitely. Other evidence-supported IBS interventions: psyllium, enteric-coated peppermint oil, gut-directed hypnotherapy, Mediterranean pattern, strain-specific probiotics (Bifidobacterium infantis 35624). Refer to a Monash-certified RDN.

7. IBD (Crohn's, UC) — EEN for pediatric induction, then patterns

IBD comprises Crohn's disease and ulcerative colitis — chronic relapsing autoimmune intestinal inflammation, distinct from IBS. Krause Ch 28 and MNHD Ch 80 (Limketkai, Parian, Mullin) treat IBD separately because the pathophysiology and dietary handles differ.

The most-cited dietary intervention is exclusive enteral nutrition (EEN) for pediatric Crohn's induction. ESPGHAN, ECCO, and NASPGHAN guidelines recommend EEN — typically 6–8 weeks of exclusively polymeric or elemental formula, no solid food — as first-line induction for pediatric mild-to-moderate Crohn's, with remission rates comparable to corticosteroids (60–80 percent) and without the growth-suppression and bone-density side effects (Critch et al., JPGN 2012). EEN is less consistently effective in adults.

The Crohn's Disease Exclusion Diet (CDED) with partial enteral nutrition excludes components hypothesized to drive dysbiosis (animal fat, wheat, dairy, emulsifiers, processed food). The Levine group's CDED RCT (Gastroenterology 2019) showed comparable pediatric remission to EEN with better tolerance.

In ulcerative colitis, patterns are more maintenance-oriented: Mediterranean, IBD-AID (UMass), and reduction of sulfur-reducing foods during active flares (sulfur-reducing bacteria produce colonocyte-toxic hydrogen sulfide; cutting red meat, eggs, sulfur-rich preservatives during flares is observational but reasonable).

Across both diseases, monitor for nutrient deficiency: iron deficiency anemia is near-universal at some point; B12 in terminal-ileal Crohn's or post-resection; vitamin D, calcium, magnesium, zinc with diarrhea; bile-acid malabsorption with terminal-ileal disease. Refer to an RDN with IBD experience.

8. Celiac disease — what gluten-free actually means

Celiac disease is a T-cell-mediated autoimmune enteropathy triggered by gluten — gliadin in wheat, hordein in barley, secalin in rye — in HLA-DQ2 or DQ8 individuals. Prevalence ~1 percent. Screening is anti-tTG IgA plus total IgA plus anti-DGP; biopsy confirms. Krause Ch 28 and MNHD Ch 81 (Hakimian and Semrad) cover MNT.

Three terms are routinely confused:

• Celiac disease is autoimmune. Gluten produces villous atrophy, malabsorption, and downstream complications (anemia, osteoporosis, infertility, EATL). Treatment is lifelong, strict, complete gluten avoidance.
• Non-celiac gluten sensitivity (NCGS) is improvement on a GFD without celiac serology, biopsy, or wheat-specific IgE. Some patients may be reacting to fructans (FODMAPs) rather than gluten (Biesiekierski et al.).
• Wheat allergy is IgE-mediated (urticaria, anaphylaxis, exercise-induced anaphylaxis). Treated by avoiding wheat — not all gluten-containing grains — and anaphylaxis preparedness.

For celiac, "gluten-free" in the U.S. is a regulatory term: the FDA defines a product as gluten-free if it contains less than 20 parts per million (20 ppm) of gluten. This is not zero — 20 ppm is the analytical detection floor of the ELISA assays in the standard methodology, matching Codex Alimentarius and the EU. Refractory patients may need to go below 20 ppm by avoiding shared facilities. Cross-contact at home (shared toasters, cutting boards, deep fryers, condiment jars) is the most common source of failure to heal.

Practical MNT: avoid wheat, barley, rye, malt, brewer's yeast, most beers; watch hidden gluten (soy sauce, modified food starch, communion wafers); replace with rice, corn, certified gluten-free oats, pseudocereals (quinoa, amaranth, buckwheat, millet, teff), and legumes; monitor iron, B12, folate, vitamin D, calcium, zinc during healing; serologic monitoring every 6–12 months. Villi heal in 1–5 years on strict avoidance. Refer to a celiac-experienced RDN.

9. Cardiovascular disease — PREDIMED and the Mediterranean pattern

PREDIMED (Prevención con Dieta Mediterránea; Estruch et al., NEJM 2013, retracted and republished 2018 with corrected statistics that didn't change the conclusions) is the strongest RCT-grade evidence base for any dietary pattern in cardiovascular prevention. It enrolled 7,447 Spanish adults at high CV risk and randomized to Mediterranean + EVOO (~50 g/day), Mediterranean + mixed nuts (~30 g/day), or low-fat control. The two Mediterranean arms reduced the primary endpoint (MI, stroke, CV death) by ~30 percent over a median 4.8 years. The trial stopped early for benefit. Substudies showed parallel benefits in cognition, breast cancer (EVOO arm), peripheral artery disease, and atrial fibrillation.

The PREDIMED pattern (Krause Appendix 22, MNHD Ch 67 Schaefer): EVOO as principal cooking fat; 7–10 servings of fruit and vegetables daily; legumes 3+ times/week; whole grains; fatty fish 3+ times/week; nuts daily; moderate red wine with meals (with the caveat that "no alcohol" is the cleaner public health message); minimal red and processed meat; minimal added sugar and ultra-processed food.

The 50 g/day EVOO dose is higher than most U.S. patients consume and is part of what makes PREDIMED's effect size unusual; olive oil's MUFA (oleic acid) and polyphenols (hydroxytyrosol, oleocanthal) are biologically active and extra-virgin is not interchangeable with refined. The earlier Lyon Diet Heart Study (de Lorgeril et al., The Lancet 1994) — secondary prevention in post-MI patients — showed 50–70 percent reduction in CV events and mortality, but PREDIMED's larger sample and primary-prevention design make it the more-cited reference.

For dyslipidemia: soluble fiber (10–25 g/day psyllium-equivalent reduces LDL 5–10 percent), plant sterols (2 g/day reduces LDL ~10 percent), elimination of trans fat (banned in the U.S. food supply since 2018). The advanced lipid panel (ApoB, NMR fractionation, Lp(a)) gives a sharper picture than total LDL-C; small-dense LDL (type B) is the atherogenic species and tracks better with refined carbohydrate than with saturated fat.

10. Eating-disorder recovery — refeeding syndrome and no "good food / bad food"

Eating disorders — anorexia nervosa (AN), bulimia nervosa (BN), binge eating disorder (BED), OSFED, ARFID — are psychiatric illnesses with potentially fatal medical complications. AN has the highest mortality rate of any psychiatric illness (5–15 percent long-term). Krause Ch 22 (Schebendach and Roth, Columbia / NYSPI) and MNHD Ch 95 are the clinical references.

The non-negotiable concern in nutritional rehabilitation is refeeding syndrome — metabolic complications when a starved patient is rapidly refed. Prolonged starvation depletes intracellular phosphate, potassium, and magnesium even while serum looks normal; refeeding triggers insulin secretion, driving these electrolytes into cells and dropping serum levels precipitously. Hypophosphatemia is the cardinal feature and can cause cardiac failure (the heart needs phosphate for ATP), respiratory failure, hemolysis, rhabdomyolysis, seizures, and death. Glucose-driven thiamine demand can expose deficiency and produce Wernicke encephalopathy.

Prevention: identify high-risk patients (BMI below 14, weight loss above 15 percent in 3 months, prolonged fasting, alcohol use disorder); start cautiously (often 10–20 kcal/kg/day for 24 hours, advancing 200–300 kcal/day across the first week); thiamine (100–300 mg/day starting before first feeding) plus B-complex / multivitamin; daily phosphate, potassium, magnesium monitoring and replacement during the first week. Modern protocols (NICE, ASPEN) favor starting nutrition with monitoring rather than withholding. Once stable, adolescent AN inpatients during weight restoration often reach 3,000–4,000 kcal/day.

The second non-negotiable is the absence of "good food / bad food" framing. Patients with eating disorders often present with rigid binary categorization (clean/dirty, safe/unsafe, healthy/forbidden) that the disorder maintains. Reinforcing this binary — even by recommending "healthier" choices — entrenches the pathology. The dietitian's job is to expand variety, reduce food-related anxiety, normalize eating rhythms, separate hunger/fullness from emotional cues, and explicitly include fear-classified foods. This is incompatible with much popular nutritional messaging, including parts of this article series for non-ED populations. The clinical dietitian adapts.

Family-Based Therapy (FBT, Maudsley) for adolescent AN gives parents meal-planning authority; the RDN consults rather than counseling the patient directly. CBT-E, classic CBT, and DBT are the principal psychotherapeutic frames. Pharmacotherapy is limited (SSRIs for comorbid anxiety/depression, lisdexamfetamine for BED, olanzapine for severe AN). Refer to a CEDS-C, CEDRD, or AED-member clinician; recovery is a team activity.

Frequently Asked Questions

Should I see a Registered Dietitian Nutritionist (RDN) or an "RD"?

Same credential. The Academy of Nutrition and Dietetics added "Nutritionist" to "Registered Dietitian" in 2013; both denote a clinician who completed a CDR-accredited program, supervised practice, and the CDR exam, licensed in 47 of 50 U.S. states. "Nutritionist" alone is unprotected. For specialty conditions look for CDCES (diabetes), CSR (renal), CEDS-C / CEDRD (eating disorders), CSO (oncology), CNSC (nutrition support), CSP (pediatrics).

What is medical nutrition therapy (MNT)?

The structured nutritional treatment of a medical condition by an RDN, built around the Nutrition Care Process — assessment, nutrition diagnosis (PES statement: Problem, Etiology, Signs/Symptoms), intervention, monitoring and evaluation — using the Academy's standardized terminology (eNCPT). Medicare Part B covers MNT for diabetes, CKD, and post-renal-transplant under defined visit limits.

Is keto a "medical diet"?

For T2D, the 2019 ADA Consensus Report recognized very-low-carb / ketogenic patterns as an evidence-supported option. For refractory pediatric epilepsy, the ketogenic diet (classical 4:1, MCT, modified Atkins, low-GI variants) is a long-established medical treatment. For Alzheimer's, glioma, PCOS, NAFLD — promising but not definitive evidence. Patients on insulin or sulfonylureas attempting keto without medication adjustment can have severe hypoglycemia within days; this is a clinician-supervised intervention when therapeutic.

Food allergy vs. food intolerance vs. food sensitivity?

Food allergy is immune-mediated, usually IgE (acute, potentially anaphylactic). The nine major U.S. allergens are milk, egg, peanut, tree nut, soy, wheat, fish, shellfish, sesame (added 2023). Diagnosis by history, skin-prick, specific IgE, sometimes oral challenge. Food intolerance is non-immune — enzyme deficiency (lactase, sucrase-isomaltase) or pharmacologic effects (caffeine, histamine, FODMAPs). Dose-dependent, not life-threatening. Food sensitivity is colloquial and clinically vague; IgG testing for "food sensitivity" is rejected by AAAAI and EAACI — IgG positivity reflects exposure, not pathology.

Is intermittent fasting evidence-based for T2D?

Moderate evidence that time-restricted eating (8–10-hour window) improves glycemic markers, particularly when the window is earlier in the day. Sutton et al. (Cell Metabolism 2018) showed improved insulin sensitivity, BP, and oxidative stress with early TRE even without weight loss. Patients on insulin or sulfonylureas need medication adjustment — hypoglycemia risk is elevated. Pregnant, breastfeeding, eating-disorder-history, and type 1 patients should not undertake prolonged fasting without specialist supervision.

Are probiotic supplements clinically useful?

Strain-specific, condition-specific, modest. Per ISAPP, "probiotic" is not a category-level claim. Specific strains have specific evidence: Bifidobacterium infantis 35624 for IBS; Saccharomyces boulardii for antibiotic-associated diarrhea and C. difficile recurrence; Lactobacillus rhamnosus GG for pediatric acute infectious diarrhea; multi-strain VSL#3 / Visbiome for pouchitis prevention. For most patients without a specific indication, fermented foods (yogurt, kefir, sauerkraut, kimchi, miso) are better-evidenced than capsules.

Why does this article keep saying "see an RDN"?

Because MNT requires individualization. Targets like "0.6–0.8 g/kg protein for pre-dialysis CKD" or "20 ppm gluten threshold for celiac" are population-level; they need translation into your foods, comorbidities, medications, and life stage. An RDN is trained to translate, monitor, and adjust. This article helps you understand what your RDN is doing — and know when something doesn't add up.

What if my physician doesn't refer me?

Ask. Medicare Part B covers MNT for diabetes and CKD without referral in many states; commercial insurance varies. The Academy of Nutrition and Dietetics's Find a Nutrition Expert directory and condition-specific organizations (Celiac Disease Foundation, Crohn's & Colitis Foundation, IAEDP) maintain credentialed lists. Telehealth has expanded access since 2020.

Sources

1. Lean, M. E. J., Leslie, W. S., Barnes, A. C., et al. "Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial." The Lancet, 2018;391(10120):541–551. Two-year follow-up: Lancet Diabetes & Endocrinology, 2019;7(5):344–355.
2. Lim, E. L., Hollingsworth, K. G., Aribisala, B. S., et al. "Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol." Diabetologia, 2011;54(10):2506–2514. Newcastle 800-kcal study.
3. Evert, A. B., Dennison, M., Gardner, C. D., et al. "Nutrition Therapy for Adults With Diabetes or Prediabetes: A Consensus Report." Diabetes Care, 2019;42(5):731–754. ADA formal recognition of low-carbohydrate options.
4. Hallberg, S. J., McKenzie, A. L., Williams, P. T., et al. "Effectiveness and safety of a novel care model for the management of type 2 diabetes at 1 year." Diabetes Therapy, 2018;9(2):583–612. Virta Health.
5. Appel, L. J., Moore, T. J., Obarzanek, E., et al. "A clinical trial of the effects of dietary patterns on blood pressure." NEJM, 1997;336(16):1117–1124. DASH.
6. Sacks, F. M., Svetkey, L. P., Vollmer, W. M., et al. "Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet." NEJM, 2001;344(1):3–10.
7. Estruch, R., Ros, E., Salas-Salvadó, J., et al. "Primary Prevention of Cardiovascular Disease with a Mediterranean Diet Supplemented with Extra-Virgin Olive Oil or Nuts." NEJM, 2018;378(25):e34 (retracted and republished from 2013). PREDIMED.
8. de Lorgeril, M., Renaud, S., Mamelle, N., et al. "Mediterranean alpha-linolenic acid-rich diet in secondary prevention of coronary heart disease." The Lancet, 1994;343(8911):1454–1459. Lyon Diet Heart Study.
9. Halmos, E. P., Power, V. A., Shepherd, S. J., Gibson, P. R., Muir, J. G. "A diet low in FODMAPs reduces symptoms of irritable bowel syndrome." Gastroenterology, 2014;146(1):67–75. Monash low-FODMAP RCT.
10. Marsh, A., Eslick, E. M., Eslick, G. D. "Does a diet low in FODMAPs reduce symptoms associated with functional gastrointestinal disorders?" European Journal of Nutrition, 2016;55(3):897–906.
11. Levine, A., Wine, E., Assa, A., et al. "Crohn's Disease Exclusion Diet Plus Partial Enteral Nutrition Induces Sustained Remission in a Randomized Controlled Trial." Gastroenterology, 2019;157(2):440–450.
12. Critch, J., Day, A. S., Otley, A., et al. "Use of enteral nutrition for the control of intestinal inflammation in pediatric Crohn disease." JPGN, 2012;54(2):298–305. EEN guidelines.
13. Choi, H. K., Willett, W., Curhan, G. "Fructose-rich beverages and risk of gout in women." JAMA, 2010;304(20):2270–2278. See also Choi & Curhan, BMJ, 2008;336:309–312 (men).
14. Sutton, E. F., Beyl, R., Early, K. S., et al. "Early Time-Restricted Feeding Improves Insulin Sensitivity, Blood Pressure, and Oxidative Stress Even without Weight Loss in Men with Prediabetes." Cell Metabolism, 2018;27(6):1212–1221.
15. Raymond, J. L., Morrow, K., eds. Krause and Mahan's Food and the Nutrition Care Process, 16th edition. Elsevier, 2023. Esp. Ch 22 (Schebendach & Roth, eating disorders), 28 (lower GI), 29 (Hasse & Matarese, hepatobiliary), 30 (Jones, diabetes), 33 (cardiovascular), 35 (Wilkens et al., renal).
16. Tucker, K. L., Duggan, C. P., Jensen, G. L., et al., eds. Modern Nutrition in Health and Disease, 12th edition. Jones & Bartlett, 2026 imprint. Esp. Ch 67 (Schaefer, lipoprotein), 68 (Andries et al., BP), 80 (Limketkai et al., IBD), 81 (Hakimian & Semrad, celiac), 95 (eating disorders), 96 (Shah et al., kidney).
17. Gropper, S. S., Smith, J. L., Carr, T. P. Advanced Nutrition and Human Metabolism, 8th edition. Cengage, 2022. Pathway biochemistry underlying MNT.
18. Lustig, R. H. Metabolical: The Lure and the Lies of Processed Food, Nutrition, and Modern Medicine (2021). Fructose-as-ethanol biochemistry; hyperinsulinemia and renal sodium retention.
19. Means, C., with Means, C. Good Energy: The Surprising Connection Between Metabolism and Limitless Health (2024). Pediatric NAFLD prevalence; fasting insulin and HOMA-IR.
20. ISAPP. Hill, C., Guarner, F., Reid, G., et al. "Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic." Nature Reviews Gastroenterology & Hepatology, 2014;11(8):506–514.

Related modules

• The metabolic-syndrome thesis: one upstream cause for many downstream diseases
• Macronutrients (core)
• Micronutrients and DRIs (core)
• Life-stage nutrition (deep dive)

Related glossary terms

• MNT (medical nutrition therapy)
• Carb counting
• DASH diet
• Low-FODMAP
• Gluten-free
• Mediterranean diet
• CKD stage
• NAFLD
• Gout
• IBD
• IBS
• Celiac